Dioxapyrrolomycin, pyrrolomycin C, pyrrolomycin D, and piericidin C2 produced by UC 1 1065 were evaluated as anthelmintics. Assays used to examine these compounds included effects on the free-living nematode Caenorhabditis elegans, ability to clear target nematodes {Haemonchus contortus and Trichostrongylus colubriformis) from jirds, and clearance of Haemonchus contortus from lambs. A crude extract of UC 11065 containing dioxapyrrolomycin, pyrrolomycin C, pyrrolomycin D, and piericidin C2 was active against C. elegans and against H. contortus in the jird. Purified and/or synthetic samples of dioxapyrrolomycin, pyrrolomycin C, pyrrolomycin D, and piericidin C2 were tested in the jird model; only dioxapyrrolomycin exhibited appreciable activity against H. contortus (^90.9% clearance at 0.33mg/jird), while none of the compounds showed appreciable activity against T. colubriformis. Dioxapyrrolomycin cleared 99.9% of H. contortus from lambs at 12.5 mg/kg. An in vitro migration study using susceptible and closantel-resistant H. contortus showed there is cross-resistance between dioxapyrrolomycin and closantel. Dioxapyrrolomycin appears to be a narrow-spectrum anthelmintic which works through a closantel-like mode-of-action. 977 In the course of screening for novel metabolites active against brine shrimp, Anemiasalina, a soil actinomycete (#9041 3, subsequently UC 1 1065) was found which produces a mixture ofdioxapyrrolomycin, pyrrolomycin C, pyrrolomycin D, and piericidin C2. The principal components produced during fermentation were evaluated in a battery of anthelmintic assays, and one of these components, dioxapyrrolomycin, was found to have appreciable anthelmintic activity. Results of those studies are reported herein.
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Materials and Methods

Producing Organism
The dioxapyrrolomycin-producing, actinomycete culture was isolated from soil obtained in Michigan, U.S.A. It was given accession number UC11065 in The Upjohn Culture Collection. The culture was stored as 4 mmdiameter agar plugs of vegetative growth (medium ISP-2, Difco) in a liquid nitrogen vapor phase freezer.
Fermentation Conditions
All fermentations were carried out in 500-ml wide-mouth Erlenmeyer flasks containing 100 ml media on a rotary shaker (250rpm, 3.8cm throw) at 28°C. The source of inoculum consisted of four 4mm diameter agar plugs (medium ISP-2, Difco) containing well-sporulated mycelial growth. This was placed in a seed medium (25 g/liter Cerelose, 25 g/liter Pharmamedia, pH 7.2 using ammoniumhydroxide), and the seed culture was incubated for 72 hours. The seed culture served as inoculum (5% v/.v rate) for shake flasks containing a production medium (20 g/liter D-galactose, 20 g/liter dextrin, lO g/liter Soytone (Difco), 2.5 g/liter Solulys (Roquette), 2 g/liter (NH4)2SO4, 2 g/liter CaCO3, pH 7.2 using potassium hydroxide). Tap water was used in preparation of seed and production media. Production cultures were incubated for 96 hours prior to harvesting.
Isolation and Purification (Scheme 1) Silica Column Chromatography: Open column silica gel chromatography was performed using 25 g silica gel (mesh 70~230) per g of Preparation A (combined methylene chloride extracts from the clear beer and mycelial cake) to be purified. The silica column was poured and equilibrated with two bed volumes w-hexane. Preparation A was absorbed onto two times its weight of silica gel and loaded onto the head of the column. The silica gel column was then eluted with two bed volumes n-hexane, followed by four bed volumes of 85% hexane: 15% EtOAc, and finished with two bed volumes EtOAc. Silica column fractions were collected in 20 ml volumes. Twenty [A column fraction aliquots were then tested for bioactivity in the A. salina assay.
Artemia salina Assay: Twenty /xl of sample was placed in a 250 jwl assay well. To this was added 160 fi\ of saline and 20//1 of an A. salina suspension, resulting in a total volume of 200/A with~20 to 30 A. salina per well. The assay well was then covered and allowed to stand for 6hours after which each well was evaluated by visualization under a binocular microscope. Scores from 0 (no dead or impaired organisms) to 5 (no live organisms) were recorded. Wells scoring 3 or higher were considered active. 40% NH4OAc (pH 4.0) for 40minutes. The column was maintained at ambient temperature with column eluate monitored by UVdetection at 254 nm. Mobile phase flow rate was maintained at 34.2 ml/minute throughout the separation. Columnfractions were collected automatically by an Isco Foxy fraction collector using peak detection (Isco 2150 Peak Separator) and 1 minute peak collection time windows. Sample solutions were pumpeddirectly onto the head of the column with maximum injection volumes of 50ml. A solution of freshly distilled pyrrole (9.0 g, 134mmol) was added and refluxed for an additional 1 hour. The reaction was cooled in an ice bath and a solution of 3,5-dichloro-2-methoxy benzoyl chloride (134mmol), triethyl amine (14.8 g, 147 mmol) in tetrahydrofuran (100ml) was added dropwise. After addition was complete, the ice bath was removed and the reaction was stirred for an additional 2 hours at room temperature. The reaction was poured onto a mixture of ice (100 g) and concentrated hydrochloric acid (10ml) and stirred for 15 minutes. The aqueous layer was extracted with chloroform (2 x 300ml), dried over sodium sulfate and filtered. The filtrate was purified via Si-60 column chromatography using a mobile phase gradient of 0-15% ethyl acetate in hexane to give 1 (10. 2,3-Dichloro-5-(3/,5/-dichloro-2'-hydroxybenzoyl)pyrrole, pyrrolomycin C (3): Sulfuryl chloride (8.8ml, 110mmol) was added dropwise to a solution of 1 (ll.8g, 44mmol) at 0°C in methylene chloride (100ml). After addition was complete (ca. 1 hour), the reaction was warmed to 20°C and stirred for an additional 1.25 hours. The reaction was concentrated to a semi-solid under reduced pressure, reconstituted in benzene (120ml), cooled to 0°C, and anhydrous aluminum chloride (14.6g, 109.7mmol) was added. The reaction mixture was stirred an additional 2hours at room temperature and poured onto ice (200g) and acidified with concentrated hydrochloric acid (10ml) to pH 3. The aqueous phase was extracted with methylene chloride (3 x 200ml), dried over anhydrous sodium sulfate and filtered. The residue was purified via trituration with ethyl acetate to give 3 (7.3g, 51%) isolated as a yellow solid (mp 220°C), (literature 220~221°C)1 2,3,4-Trichloro-5-(3/,5'-dichloro-2/-hydroxybenzoyl)pyrrole, pyrrolomycin D (4). A solution of sulfuryl chloride (1.7 g, 12.3 mmol) in methylene chloride (5 ml) was added to a stirred solution of 1 (1.0 g, 3.7mmol) at 0°C in methylene chloride (25ml) at 0°C. The reaction mixture was immediately warmed to room temperature and stirred an additional 5 hours. The reaction mixture was concentrated under reduced pressure and triturated with hexane to give a solid (200mg, 15% crude yield) consisting of trichlorinated pyrrole and dichlorinated pyrrole isomers in a 4 : 1 ratio. Anhydrous aluminum chloride (150mg, 1.1 mmol) was added to a suspension of this material in benzene (5 ml) at 0°C. The reaction was stirred an additional 1.5hours at 20°C and then was poured onto a mixture of ice (50g) and concentrated hydrochloric acid (4ml). The aqueous portion was extracted with methylene chloride (2 x 50ml) and dried over anhydrous sodium sulfate. The filtrate was purified by Si-60 column chromatography using a mobile phase gradient of0-80% ethyl acetate in hexane to give 4 isolated as a yellow solid (75mg, 6% yield), Caenorhabditis elegans Assay: The free-living nematode C. elegans was used as a primary anthelmintic assay. This assay has been described by Simpkin and Coles2) . Activity at 50 ppm moves a test material to in vivo evaluation.
Haemonchus contortusI Trichostrongylus colubriformis/Jird Assay: The jird model was used as an initial in vivo anthelmintic assay. This model utilizedjirds infected with two important target parasites of ruminants, H. contortus and T. colubriformis (anthelmintic-sensitive or -resistant wormscan be used). Initially, activity was assessed only against H. contortus as described by Conder et al.3\ while follow-up studies examined activity against both parasites using the techniques outlined by Conder et a/.4). A test material was considered highly active if it produced a clearance of^90% at^lmg/jird for either parasite.
Cross-resistance with benzimidazoles, ivermectin, and levamisole was examined as described for levamisole by Conder et al.5). Haemonchuscontortus/Sheep Assay: Lambs monospecifically infected with H. contortus was used to evaluate materials. Purpose bred, helminth-free lambs were procured. These lambs were treated with ivermectin (0.2 mg/kg, subcutaneously), vaccinated for sore mouth, and placed in a single, community pen. Three weeks later each lamb was treated with levamisole hydrochloride (8.0mg/kg, per os). Two weeks after treatment with levamisole, all lambs were inoculated per os with~7,500 infective larvae of H. contortus. Rectal fecal samples were taken from each lamb 1 to 3 days prior to infection, and these were examined using the double centrifugation technique to verify that the animals were free of trichostrongyles prior to infection. On day 32~34 postinoculation (PI), a rectal fecal sample from each lamb was examined again using the McMastercounting chamber technique to verify infection; those animals which did not exhibit suitable infection were dropped from the study. Remaining lambs were treated per os on day 35 PI; 4~5 animals received vehicle only. Prior to administration, test materials were prepared in a manner suitable for the substance being examined. All lambs were monitored for toxic signs following treatment. Lambs were killed 7 days after treatment (day 42PI), and the abomasum was ligated and removed from each animal. Each abomasumwas longitudinally sectioned and the contents rinsed into an 80 mesh sieve. Sieve contents were collected in individual containers and fixed in formol-alcohol. Later each sample was transferred to a 1,000-ml graduated cylinder and the volume was brought to 400~1,000ml with tap water. The total number of wormsin a 10% aliquot was determined. If no wormswere found in the 10%aliquot, the entire sample was examined. Total wormnumber/lamb and percentage clearance for each treatment were calculated. Percentage clearance was determined according to the following formula:
Percentage clearance = [(Mean number of wormsrecovered from vehicle control lambs -number of wormsrecovered from treated lamb)/mean numberof wormsrecovered from vehicle control lambs] x 100.
A substance was considered highly active if its clearance was^90% and moderately active if its clearance was^70 but <90%.
Haemonchus contortus Migration Assay: Fourth-stage larvae of closantel-resistant (H41) and -susceptible (McM)strains of H. contortus were exposed to drugs over 2 or 3 days and viability assessed by counting the number of larvae either passing through or retained by a 50 fim aperture nylon mesh at 37°C. Concentrations required to inhibit migration of 50% of the worms (MIC50) were calculated from a best fit curve to a plot of logit of response to log concentration6*.
Results
The UC 1 1065 fermentation was processed according to Scheme 1. Final structure elucidation was carried out for each compound using IR, UV, MS, and NMRtechniques. Elemental analysis and ORD spectroscopy methodswere used for the analysis ofdioxapyrrolomycin. In all cases, results were in agreement with the published data of dioxapyrrolomycin7'8), pyrrolomycin C1'9*, and piericidin C210'11).
Synthesis of pyrrolomycin C was accomplished by using a modification of a procedure by Koyama et al.^. Pyrrole magnesium bromide was reacted with 3,5-dichloro-2-methoxy benzoyl chloride to give 1.
Chlorination of this intermediate with SO2C12at 0°C followed by demethylation with A1C13produced pyrrolomycin C in 51%yield. Our results are in contrast to work by Koyamaet al.1^, whoreport the production of pyrrolomycin C and it's trichlorinated analog pyrrolomycin D in 18 and 16% yields, respectively, when chlorination is performed at 20°C. We have found that yields of pyrrolomycin C can generally be improved with chlorination at 0°C. The trichlorinated analog, pyrrolomycin D, was obtained in low yield (6%) with SO2C12when chlorination was performed at 20°C.
A crude extract of UC 11065 containing several components, including dioxapyrrolomycin, Dvrrolomvcin C. ovrrolomvcin D. and niericidin CU, was examined for anthelmintic activitv against the Table 1 . Percentage clearance of Haemonchuscontortus and Trichostrongylus colubriformis from jirds inoculated per os with~1,000 exsheathed, infective larvae of each parasite, treated per os with dioxapyrrolomycin, pyrrolomycin C, pyrrolomycin D, or piericidin C2 on day 10 postinoculation (PI) and necropsied on day 1 3 PI. free-living nematode C. elegans and was found to be highly active at 50ppm. Based on this response against C. elegans, the crude preparation was evaluated against a target parasite, H. contortus, in the jird. At 2.5mg/jird, >99% clearance of parasites was achieved in treated jirds compared to vehicle treated animalsand no toxic signs were observed.
A program was initiated to isolate and identify the active component(s) produced by UC11065, Table 1 shows results obtained against H. contortus and a second target parasite, T. colubriformis in the jird model for the 4 main components of the crude preparation described above, i.e. dioxapyrrolomycin, pyrrolomycin C, pyrrolomycin D, and piericidin C2. Although pyrrolomycin C and piericidin C2 cleared 62.1% ofH. contortus at~1.0mg/jird and pyrrolomycin D cleared 0%ofH. contortus at O.ll mg/jird (it killed all jirds given a higher dose), dioxapyrrolomycin exhibited strong activity (^90.9% clearance at 0.33 mg/jird) against this parasite, which could readily explain results obtained with the crude preparation. It also is worth noting that although neither dioxapyrrolomycin nor pyrrolomycin C are highly active against T. colubriformis, both have a hint of activity against this parasite (41.5% clearance at 0.33 mg/jird and 33.5~56.2% clearance at~1.0mg/jird, respectively).
Dioxapyrrolomycin and pyrrolomycin C were examinedin sheep monospecifically infected with Table 2 -Percentage clearance of Haemonchus contortus H. contortus. Data from these studies are shown in Jirds infected with ivermectin/benzimidazoleor levamisole/benzimidazole-resistant H. contortus were used to examinewhether dioxapyrrolomycin has cross-resistance with any of the 3 major classes of broad-spectrum anthelmintics.
Data presented in Table 3 show that dioxapyrrolomycin has from lambs monospecifically inoculated per os with 7,500 infective larvae of the parasite, treated per os with dioxapyrrolomycin or pyrrolomycin C on day 35 postinoculation (PI), and necropsied on day 42 PI. Range indicates multiple studies. Closantel (SmithKline Beecham), Levamisole (Sigma H. contortus. Dioxapyrrolomycin and pyrrolomycin Chemical Co.). C appear to have some, albeit very weak, activity against a second ruminant parasite, T. colubriformis, in the jird model, suggesting that manipulation (synthetically or semisynthetically) of the template provided by the "pyrrolomycin" class may provide a novel broad-spectrum anthelmintic. Although lack of cross-resistance with the 3 major classes of broadspectrum anthelmintics has been demonstrated for dioxapyrrolomycin, migration studies in vitro have shown that dioxapyrrolomycin is cross-resistant with closantel (thought to uncouple electron-transportassociated phosphorylation12)), the primary narrow-spectrum drug used to control H. contortus in the field. Based on these data, dioxapyrrolomycin appears to be a narrow-spectrum anthelmintic which works through a closantel-like mode-of-action.
